Località la Schiana, Pozzuoli (NA), Italy Clinical Trials — 8 Studies

Filter these 8 trials by phase, condition, sponsor and more.

Open in Search →

Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting

2024-519669-23-00 4 2025-09-29 Patients with metastatic colorectal cancer (mCRC) RAS-mutant
Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi … Recruiting

2024-514420-16-00 4 2024-12-18 RAS/BRAF wild-type metastatic colorectal cancer
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 5 2024-06-12 Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting

2024-511397-70-00 4 2024-05-06 metastatic renal cell carcinoma (mRCC)
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva … Recruiting

2024-513372-18-00 4 2019-10-18 Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA … Recruiting

2024-518987-11-00 4 2019-06-12 ADCC
REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients … Ended recruitment

2024-516844-25-01 4 2019-01-03 Patients with ras-mutated metastatIc colorectal cancer
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer

Showing 1–8 of 8 trials